

| | |
|---|-----|
| INTRODUCTION | XI |
| STUDY GOALS AND OBJECTIVES..... | XI |
| REASONS FOR DOING THE STUDY | XI |
| CONTRIBUTION OF THE STUDY AND FOR WHOM | XI |
| SCOPE AND FORMAT | XI |
| METHODOLOGY | XII |
| RELATED BCC STUDIES | XII |
| EXECUTIVE SUMMARY | XIV |
| PRESCRIPTION ANTIVIRAL DRUGS: MAJOR MARKETS | |
| SUMMARY | XIV |
| INDUSTRY OVERVIEW..... | 1 |
| HISTORY AND GROWTH OF THE ANTIVIRAL DRUGS MARKET..... | 1 |
| STRUCTURAL VIROLOGY | 1 |
| VIRAL REPLICATION | 2 |
| Poliomyelitis | 3 |
| Poliovirus Vaccines..... | 4 |
| Influenza | 4 |
| DEFINITION OF VIRUSES..... | 5 |
| Invading the Body | 6 |
| Virus Categories | 6 |
| VIRAL DISEASES | 9 |
| Acquired Immune Deficiency Syndrome | 10 |
| Hepatitis | 11 |
| Hepatitis A | 12 |
| Hepatitis B..... | 12 |
| Hepatitis C | 13 |
| Hepatitis D..... | 13 |
| Hepatitis E | 13 |
| Hepatitis G..... | 14 |
| Influenza | 14 |
| Herpes | 15 |
| Herpes Type 1 and 2 | 15 |
| Mononucleosis..... | 16 |
| Condylomata Acuminata..... | 16 |
| DEMOGRAPHICS..... | 17 |
| HIV | 19 |
| Hepatitis..... | 20 |
| Herpes | 20 |
| HPV | 20 |
| Influenza | 21 |
| Malaria..... | 21 |
| Other Viruses..... | 21 |

| | |
|---|----|
| FINANCIAL IMPACT..... | 22 |
| TRENDS AFFECTING THE MARKET | 23 |
| HIV-Combination Therapies | 23 |
| Logistical/Administrative/Legal Issues for Drug Development..... | 24 |
| Development Priorities | 24 |
| Structured Intermittent Therapy | 25 |
| Garlic Supplements | 26 |
| Chinese Generic HIV Drugs..... | 26 |
| Price Reductions in HIV Drugs..... | 27 |
| Price Wars..... | 27 |
| NUCLEOSIDE ANALOGS AND NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | 28 |
| OVERVIEW..... | 28 |
| PRODUCT DESCRIPTIONS..... | 28 |
| LAMIVUDINE/ZIDOVUDINE | 29 |
| LAMIVUDINE..... | 30 |
| HIVID | 30 |
| RIBAVIRIN/INTERFERON ALPHA-2B, RECOMBINANT INJECTION | 31 |
| ZIDOVUDINE | 31 |
| VALGANCICLOVIR | 31 |
| VALACYCLOVIR | 32 |
| DIDANOSINE | 32 |
| RIBAVIRIN | 33 |
| LAMIVUDINE..... | 33 |
| STAVUDINE | 33 |
| ABACAVIR | 34 |
| ACYCLOVIR..... | 34 |
| RESEARCH AND DEVELOPMENT | 35 |
| ADEFOVIR DIPIVOXIL | 35 |
| ADEFOVIR..... | 36 |
| RIBAVIRIN | 36 |
| ZIDOVUDINE | 37 |
| VALGANCICLOVIR | 37 |
| LDT | 38 |
| DAPD | 38 |
| BETA-L-FD4C | 38 |
| MARKET SIZE AND GROWTH | 39 |
| TOTAL MARKET BY GEOGRAPHIC REGION | 41 |
| U.S. Market..... | 42 |
| European Union Market | 43 |
| Japan Market..... | 43 |
| Rest of World Market | 43 |

| | |
|---|----|
| COMPETITIVE STRUCTURE AND MARKET SHARE..... | 44 |
| NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | 46 |
| OVERVIEW..... | 46 |
| PRODUCT DESCRIPTIONS..... | 46 |
| DELAVIRDINE | 46 |
| EFAVIRENZ..... | 47 |
| ABACA VIR/ZIDOVUDINE/LAMIVUDINE COMBINATION..... | 47 |
| NEVIRAPINE..... | 47 |
| RESEARCH AND DEVELOPMENT | 48 |
| EMTRICITABINE..... | 48 |
| EMIBIRINE..... | 48 |
| HBY-097 | 48 |
| CAPRAVIRINE | 48 |
| NNRTI, DPC961 AND DPC083..... | 49 |
| MARKET SIZE AND GROWTH | 49 |
| TOTAL MARKET BY GEOGRAPHIC REGION | 50 |
| U.S. Market..... | 52 |
| European Union Market | 52 |
| Japan Market..... | 52 |
| Rest of World Market | 52 |
| COMPETITIVE STRUCTURE AND MARKET SHARE..... | 53 |
| PROTEASE INHIBITORS | 55 |
| OVERVIEW..... | 55 |
| PRODUCT DESCRIPTIONS..... | 55 |
| AMPRENAVIR | 56 |
| INDIAVIR..... | 56 |
| SAQUINAVIR..... | 56 |
| LOPINAVIR..... | 57 |
| RITONAVIR | 57 |
| NELFINAVIR..... | 58 |
| RESEARCH AND DEVELOPMENT | 58 |
| RITONAVIR | 58 |
| ATAZANAVIR | 59 |
| AGENERASE | 59 |
| MERIMEPODIB..... | 59 |
| VX-950 | 60 |
| TIPRANAVIR | 60 |
| MARKET SIZE AND GROWTH | 61 |
| TOTAL MARKET BY GEOGRAPHIC REGION | 62 |
| U.S. Market..... | 63 |
| European Union Market | 63 |
| Japan Market..... | 64 |
| Rest of World Market | 64 |

| | |
|--|----|
| COMPETITIVE STRUCTURE AND MARKET SHARE..... | 64 |
| OTHER ANTIVIRAL DRUGS..... | 66 |
| OVERVIEW..... | 66 |
| PRODUCT DESCRIPTIONS..... | 66 |
| IMIQUIMOD | 67 |
| CMV-IGIV..... | 67 |
| PENCICLOVIR | 67 |
| FAMICLOVIR..... | 67 |
| RIMANTADINE | 67 |
| FOSCARNET..... | 68 |
| INTERFERON ALFACON-1 | 68 |
| ZANAMIRVIR | 68 |
| RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN..... | 68 |
| AMANTADINE..... | 69 |
| PALIVIZUMAB | 69 |
| OSELTAMIVIR PHOSPHATE | 69 |
| CIDOFOVIR | 69 |
| TENOFVIR DF | 70 |
| RESEARCH AND DEVELOPMENT | 70 |
| PLECONARIL..... | 70 |
| PICOVIR..... | 71 |
| AG7088 | 71 |
| VP50406..... | 71 |
| ME609..... | 72 |
| PAPIRINE | 72 |
| PEGASYS AND RIBAVIRN, PEGASYS AND CEPLENE..... | 72 |
| POLYPHENONE | 72 |
| T-20 AND T-1249 | 73 |
| AMPLIGEN | 73 |
| POLY A POLY U | 73 |
| OMEGA INTERFERON | 74 |
| MULTIKINE | 74 |
| MARKET SIZE AND GROWTH | 75 |
| TOTAL MARKET BY GEOGRAPHIC REGION | 76 |
| U.S. Market..... | 78 |
| European Union Market | 78 |
| Japan Market..... | 78 |
| Rest of World Market | 78 |
| COMPETITIVE STRUCTURE AND MARKET SHARE..... | 79 |
| TECHNOLOGY | 81 |
| CURRENT USES OF TECHNOLOGY | 81 |
| GENETIX REAGENT | 82 |
| TITAN PHARMACEUTICALS/NEW YORK UNIVERSITY..... | 82 |

| | |
|---|-----|
| BIOSHIELD TECHNOLOGIES | 82 |
| OXFORD BIOMEDICA..... | 83 |
| HEPAVEC AND DEVELOGEN | 83 |
| CONNAUGHT LABORATORIES | 83 |
| PHENOTYPING TESTS..... | 84 |
| PATENTS | 84 |
| NEW TECHNOLOGY DEVELOPMENT | 85 |
| THE OVERALL PRESCRIPTION ANTIVIRAL MARKET..... | 86 |
| TOTAL MARKET FOR PRESCRIPTION ANTIVIRAL DRUGS | 86 |
| TOTAL MARKET PERCENT DISTRIBUTION BY PRODUCT TYPE | 89 |
| TOTAL MARKET PERCENT DISTRIBUTION BY REGION..... | 90 |
| INDUSTRY STRUCTURE | 92 |
| PARTICIPANTS AND COMPETITIVE ANALYSIS..... | 92 |
| PRODUCT ANALYSIS | 93 |
| COMPANY PROFILES..... | 95 |
| Abbott Laboratories, Inc..... | 95 |
| AstraZeneca PLC..... | 96 |
| Boehringer Ingelheim GmbH (Roxane Laboratories, Inc.)..... | 96 |
| Roxane Laboratories, Inc. | 97 |
| Bristol-Myers Squibb Company (DuPont Pharmaceuticals Company)..... | 97 |
| DuPont Pharmaceuticals Company..... | 98 |
| Glaxosmithkline PLC | 98 |
| Merck & Company, Inc..... | 99 |
| Novartis AG (Novartis Pharmaceuticals Corporation)..... | 99 |
| Novartis Pharmaceuticals Corporation | 99 |
| Roche Group (Hoffmann-La Roche, Inc.)..... | 100 |
| Hoffmann-La Roche, Inc..... | 100 |
| Schering-Plough Corporation..... | 101 |
| Pfizer, Inc. (Agouron Pharmaceuticals, Inc.)..... | 101 |
| APPENDICES..... | 103 |
| APPENDIX I | 103 |
| MAJOR PRESCRIPTION ANTIVIRAL DRUG MANUFACTURERS..... | 103 |
| 3M Pharmaceuticals | 103 |
| Abbott Laboratories, Inc..... | 103 |
| Agouron Pharmaceuticals, Inc. | 103 |
| Amgen, Inc. | 104 |
| Astrazeneca PLC | 104 |
| Boehringer Ingelheim GmbH..... | 104 |
| Bristol-Myers Squibb Company | 104 |
| DuPont Pharmaceuticals, Inc. | 104 |

| | |
|--|-----|
| Endo Pharmaceuticals, Inc. | 105 |
| Forest Pharmaceuticals, Inc. | 105 |
| Gilead Sciences, Inc. | 105 |
| GlaxoSmithKline PLC | 105 |
| Hoffmann-La Roche, Inc. | 105 |
| ICN Pharmaceuticals, Inc. | 106 |
| MedImmune, Inc. | 106 |
| Merck & Company, Inc. | 106 |
| Novartis AG | 106 |
| Novartis Pharmaceuticals Corporation | 106 |
| Pfizer, Inc. | 107 |
| Roche Group | 107 |
| Roxane Laboratories, Inc. | 107 |
| Schering-Plough Corporation | 107 |
| APPENDIX II | 107 |
| OTHER MANUFACTURERS AND COMPANIES | 107 |
| Achillion Pharmaceuticals, Inc. | 108 |
| Aspen Pharmacare Holding, Ltd. | 108 |
| Aventis Pharma | 108 |
| Bayer Corporation | 108 |
| Shire-BioChem, Inc. (formerly BioChem Pharma, Ltd.) | 108 |
| BioMedicines, Inc. | 109 |
| BioShield Technologies, Inc. | 109 |
| Bukwang Pharmaceutical Company, Ltd. | 109 |
| Catalytica Pharmaceuticals, Inc. | 109 |
| CEL-SCI Corporation | 109 |
| Connaught Laboratories, Inc. | 110 |
| DeveloGen AG | 110 |
| Eli Lilly & Company | 110 |
| Genentech, Inc. | 110 |
| Genetix Group plc | 110 |
| Hemispherx Biopharma, Inc. | 111 |
| HepaVec AG | 111 |
| Hetero Drugs, Ltd. | 111 |
| Maxim Pharmaceuticals, Inc. | 111 |
| MediGene AG | 111 |
| Medivir AB | 112 |
| Northeast General Pharmaceutical Factory | 112 |
| Novirio Pharmaceuticals, Inc. | 112 |
| Oxford BioMedica Ltd. | 112 |
| Pentose Pharmaceuticals, Inc. | 112 |
| Pharmacia Corporation | 113 |
| Schering AG | 113 |
| Shanghai Desano Biopharmaceutical Company | 113 |

| | |
|---|-----|
| Sumitomo Pharmaceuticals | 113 |
| Takeda Chemical Industry, Ltd. | 113 |
| Titan Pharmaceuticals, Inc. | 113 |
| Triangle Pharmaceuticals, Inc. | 114 |
| Vertex Pharmaceuticals, Inc. | 114 |
| Virco Laboratories, Inc. | 114 |
| ViroLogic, Inc. | 114 |
| ViroPharma, Inc. | 114 |
| Warner-Lambert Company: Pfizer, Inc. | 115 |
| Wyeth | 115 |
| APPENDIX III | 115 |
| ASSOCIATION AND ORGANIZATIONS | 115 |